valyl-valine | 3918-93-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: valyl-valine
• 英文别名: valylvaline；optically inactive N-valyl-valine；Opt.-inakt.N-Valyl-valin；N-Valyl-valin；Valyl-valin；Val-Val；2-[(2-Azaniumyl-3-methylbutanoyl)amino]-3-methylbutanoate
• CAS: 3918-93-2
• 化学式: C₁₀H₂₀N₂O₃
• 分子量: 216.28
• InChiKey: KRNYOVHEKOBTEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  valyl-valine 生成 N-(N-benzoyl-valyl)-valine
  参考文献：
  名称：

  Tollin et al., Archives of Biochemistry, 1959, vol. 79, p. 206,207

  摘要：

  DOI：
• 作为产物：
  描述：

  N-苄氧羰基-DL-缬氨酸 在 甲醇 、 sodium hydroxide 、 乙醚 、 三正丁胺 、 氯甲酸乙酯 、 钯 作用下， 生成 valyl-valine
  参考文献：
  名称：

  Davis, Annales de Chimie (Cachan, France), 1954, vol. <12> 9, p. 399,426

  摘要：

  DOI：

文献信息

• Organic compounds
  申请人：Speedel Experimenta AG

  公开号：EP1908761A1

  公开（公告）日：2008-04-09

  The present invention relates to substituted piperidines of the general formula (I), where R1, R2, R3, R4, R5, Q and X have the definitions elucidated in more detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors. Moreover, the enzymatic substrate portion of the compound is simultaneously a substrate for a membrane transporter.

  本发明涉及一般式（I）的取代哌啶化合物， 其中R1、R2、R3、R4、R5、Q和X的定义在描述中有更详细的阐明，以及它们的制备方法和这些化合物作为药物的用途，特别是作为肾素抑制剂。此外，化合物的酶底物部分同时也是膜转运体的底物。
• Amino alcohols and their use as renin inhibitors
  申请人：Speedel Experimenta AG

  公开号：EP1911762A1

  公开（公告）日：2008-04-16

  The invention provides substituted amino alcohols of the general formula (I) and the salts thereof, preferably the pharmaceutically acceptable salts thereof; where R2, R3, Q, T, X and Z have the definitions elucidated in more detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors. Moreover, the enzymatic substrate portion of the compound is simultaneously a substrate for a membrane transporter.

  本发明提供了一般式(I)及其盐的取代氨基醇，优选为其药学上可接受的盐。其中，R2、R3、Q、T、X和Z的定义在说明书中有更详细的阐述，以及其制备方法和这些化合物作为药物的用途，特别是作为肾素抑制剂。此外，该化合物的酶底物部分同时也是膜转运体的底物。
• METHOD FOR PRODUCING GAMMA -GLUTAMYL-VALYL-GLYCINE CRYSTAL
  申请人：AJINOMOTO CO., INC.

  公开号：US20150361133A1

  公开（公告）日：2015-12-17

  The present invention provides a method for efficiently producing a γ-glutamyl-valyl-glycine crystal. Specifically, the present invention provides a method for producing a γ-glutamyl-valyl-glycine crystal, which includes the steps of: preparing a mixed solution of valyl-glycine or a salt thereof and γ-glutamyl-valyl-glycine, wherein the mixed solution contains valyl-glycine or the salt thereof in an amount of 20 mass % or more relative to the mass of γ-glutamyl-valyl-glycine; adjusting the amount of valyl-glycine or the salt thereof in the prepared mixed solution to 0.1 mass % or more and less than 20 mass % relative to the mass of γ-glutamyl-valyl-glycine to prepare a γ-glutamyl-valyl-glycine solution; and subjecting the γ-glutamyl-valyl-glycine solution to a crystallization procedure to produce the γ-glutamyl-valyl-glycine crystal.

  本发明提供了一种高效生产γ-谷氨酰-缬氨酸-甘氨酸晶体的方法。具体来说，本发明提供了一种生产γ-谷氨酰-缬氨酸-甘氨酸晶体的方法，包括以下步骤：制备缬氨酸-甘氨酸或其盐和γ-谷氨酰-缬氨酸的混合溶液，其中混合溶液中缬氨酸或其盐的质量占γ-谷氨酰-缬氨酸质量的20%或以上；调整制备的混合溶液中缬氨酸或其盐的量，使其相对于γ-谷氨酰-缬氨酸的质量为0.1%或以上但小于20%；将γ-谷氨酰-缬氨酸溶液经过结晶程序进行结晶，生产γ-谷氨酰-缬氨酸晶体。
• Novel spergualin-related compounds and process for producing the same
  申请人：MICROBIAL CHEMISTRY RESEARCH FOUNDATION

  公开号：EP0241797A2

  公开（公告）日：1987-10-21

  The present invention relates to novel Spergualin-related compounds represented by the general formula [I] R2 is a residue obtained by removing, from an amino acid or peptide, the hydroxyl group of the carboxyl group and, when R, is a group other than -H, R2 is same as R, , or a pharmacologically acceptable salt thereof. Said compounds or salts thereof have an immune-modulating action. The invention further relates to pharmaceutical formulations having an immuno-modulating activity which contain such Spergualin-related compounds and a process for the manufacture of these compounds and preparations.

  本发明涉及由通式[I]表示的新型 Spergualin 相关化合物 R2 是通过从氨基酸或肽中去除羧基的羟基而得到的残基，当 R 是除-H 以外的基团时，R2 与 R 相同，或其药理上可接受的盐。上述化合物或其盐具有免疫调节作用。 本发明还涉及具有免疫调节活性的药物制剂，其中含有此类与 Spergualin 相关的化合物，以及制造这些化合物和制剂的工艺。
• New spergualin-related compound and pharmaceutical composition
  申请人：ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI

  公开号：EP0309971A2

  公开（公告）日：1989-04-05

  The present invention relates to new spergualin-related compounds having an immunopotentiating effect and represented by the general formula [I]: wherein X represents -(CH2)3-5- or R represents -H or -CH2-OH and R1 and R2 each represents a residue formed by removing a hydroxyl group from the carboxyl group of an amino acid or peptide with the proviso that both of R1 and R2 cannot represent at the same time, and pharmacologically acceptable salts thereof.

  本发明涉及具有免疫增强作用并由通式[I]表示的新的 spergualin 相关化合物： 其中 X 代表-(CH2)3-5-或 R代表-H或-CH2-OH，R1和R2各自代表通过从氨基酸或肽的羧基上除去羟基而形成的残基，但R1和R2不能同时代表 的残基、 及其药理上可接受的盐类。